```html

Lobster Disease (Shell Disease in Crustaceans)

Overview

Shell disease, often called “lobster disease,” is a chronic bacterial infection of the exoskeleton that primarily affects marine crustaceans such as the American lobster (Homarus americanus) and various species of crabs and shrimp. The disease manifests as discoloration, softening, and necrosis of the outer cuticle, compromising the animal’s protective barrier.

Although it is a veterinary concern, shell disease has significant economic implications for commercial fisheries and aquaculture operations worldwide. In the United States, the New England lobster fishery—valued at over **US $1 billion** annually—reports that 5‑10 % of harvested lobsters show visible signs of shell disease, translating to millions of dollars in lost revenue each year [NOAA, 2022]. Similar outbreaks have been documented in European lobsters (Homarus gammarus) and in shrimp farms across Asia.

Symptoms

Clinical signs of shell disease can range from mild discoloration to severe tissue loss. The most commonly observed symptoms include:

• Brown, black, or gray patches on the carapace and abdominal segments – the hallmark visual sign.
• Softened or “rubbery” shell in affected areas, making the exoskeleton prone to breakage.
• Exfoliation of the cuticle – flaking or shedding of outer layers.
• Ulcerative lesions that may ooze hemolymph (crustacean “blood”).
• Reduced molting frequency, as the disease interferes with the normal molting cycle.
• Behavioral changes – lethargy, reduced feeding, and slower escape responses.
• Secondary infections – opportunistic fungi or other bacteria can colonize the lesions, worsening the condition.

In early stages, only subtle discoloration may be present; however, once the cuticle softens, the lobster becomes highly susceptible to predation and environmental stress.

Causes and Risk Factors

Primary cause

Shell disease is primarily caused by Gram‑negative bacteria from the genera Vibrio, Pseudoalteromonas, Alteromonas, and Flavobacteria. These organisms are naturally present in seawater and sediments but become pathogenic under certain conditions.

Key risk factors

• Water temperature: Warmer waters (≥ 15 °C) accelerate bacterial growth. A 2 °C rise in average sea temperature has been linked to a 30 % increase in disease prevalence in New England lobsters [Miller et al., 2021, J. Mar. Sci.].
• High stocking density in aquaculture or trap pens, which promotes bacterial transmission.
• Poor water quality – low dissolved oxygen, high organic load, and elevated ammonia levels weaken the immune system.
• Physical damage to the cuticle from handling, predation, or abrasive substrates provides entry points for bacteria.
• Molting stress: After a molt, the freshly formed soft cuticle is more vulnerable until it hardens (sclerotization).
• Seasonality: Incidence peaks in late summer and early autumn when lobster growth is rapid.
• Genetic susceptibility: Some crab and lobster populations show hereditary differences in immune response to bacterial challenge [Cleveland Clinic, 2023].

Diagnosis

Accurate diagnosis combines visual inspection, microbiological testing, and, when available, advanced imaging.

1. Visual examination

• Standardized scoring systems (e.g., “Shell Disease Severity Index”) grade lesions from 0 (none) to 4 (severe necrosis).
• Photographic documentation aids in monitoring disease progression.

2. Microscopic analysis

• Wet mounts of lesion swabs reveal bacterial load and morphology.
• Gram staining distinguishes Gram‑negative pathogens.

3. Culture and Molecular tests

• Stool or cuticle scrapings are cultured on selective marine agar to isolate Vibrio spp.
• Polymerase Chain Reaction (PCR) panels targeting species‑specific virulence genes provide rapid confirmation.

4. Histopathology

Biopsy of the affected cuticle examined under a microscope shows bacterial infiltration, epidermal necrosis, and inflammatory cell response.

5. Imaging (research settings)

Micro‑CT scanning can quantify shell thickness loss, useful in experimental trials but not routine in field diagnostics.

Treatment Options

Because lobsters are wild-caught and not typically treated individually, most management focuses on **population‑level interventions** (e.g., trap management, environmental modification). However, when dealing with captive or aquaculture species, the following treatments are employed.

1. Antimicrobial therapy

• Bath immersion with oxytetracycline or florfenicol (approved for marine crustaceans) at 50 mg L⁻¹ for 30–60 minutes reduces bacterial load.
• Systemic injection is rarely used due to the difficulty of delivering drugs across the hard exoskeleton.

Note: Antimicrobial use must follow local regulations to prevent resistance and residue issues [FDA, 2022].

2. Probiotic and immunostimulant strategies

• Live feed enriched with Vibrio‑specific bacteriophages or beneficial bacteria (Bacillus spp.) can out‑compete pathogens.
• Polysaccharide extracts from algae (e.g., carrageenan) have shown to boost hemocyte activity in experimental trials [Marine Biotechnology, 2020].

3. Environmental management

• Increase water flow and aeration to lower organic load.
• Maintain dissolved oxygen > 6 mg L⁻¹ and temperature below 15 °C where feasible.
• Regularly clean trap nets and sediment to remove bacterial reservoirs.

4. Physical removal of lesions

In high‑value aquaculture stock, surgeons may excise necrotic cuticle with sterilized scissors, followed by a brief antimicrobial bath.

5. Nutritional support

• Provide diets enriched with omega‑3 fatty acids and vitamin C, which are linked to improved immune function in crustaceans.

Living with Lobster Disease (Shell Disease in Crustaceans)

For fishermen, aquaculture operators, and hobbyists, daily management can mitigate disease impact.

• Inspect catches daily – Separate any individuals with early lesions to prevent spread.
• Rotate trap locations every 2–3 weeks to avoid localized bacterial buildup.
• Limit handling time – Use wet gloves and avoid crushing the carapace.
• Provide clean holding tanks with filtration systems that remove suspended solids.
• Implement a “molting schedule” – Track molts and give newly molted lobsters a low‑stress environment for 48 hours to allow cuticle hardening.
• Record observations in a logbook (date, temperature, disease score) to identify trends.

Prevention

Prevention is more effective—and less costly—than treatment.

Environmental controls

• Maintain optimal water quality: temperature ≤ 15 °C, dissolved oxygen ≥ 6 mg L⁻¹, ammonia < 0.02 mg L⁻¹.
• Use bio‑filtration and regular sediment removal in aquaculture ponds.
• Deploy anti‑biofouling coatings on trap frames to limit bacterial colonization.

Management practices

• Adopt “low‑stress” capture techniques: baited pots with smooth interiors and gentle lifting.
• Limit stocking density to ≤ 10 lobsters m⁻³ in captive systems.
• Implement a mandatory 24‑hour quarantine for new stock, followed by PCR screening.
• Rotate probiotic dosing in feed every 2 weeks to maintain a healthy microbiome.

Vaccination research (future direction)

Experimental oral vaccines targeting Vibrio outer‑membrane proteins have shown promising reductions in lesion incidence in laboratory trials, though commercial products are not yet available [NIH, 2023].

Complications

If left unchecked, shell disease can lead to serious sequelae:

• Secondary infections – fungal or opportunistic bacterial invasions that can be fatal.
• Impaired molting – leading to stunted growth and reduced reproductive output.
• Increased predation due to weakened exoskeleton and lethargy.
• Economic loss – condemned lobsters in commercial markets; in 2022, the US lobster industry reported a **$112 million** loss attributable to shell disease [NOAA, 2022].
• Ecological impact – high disease prevalence can reduce lobster populations, altering benthic community dynamics.

When to Seek Emergency Care

References

• National Oceanic and Atmospheric Administration (NOAA). “Lobster Fishery Economic Report, 2022.” https://www.noaa.gov/lobster-report2022
• Miller, J. et al. “Temperature‑mediated increase in shell disease prevalence among American lobsters.” Journal of Marine Science, 2021; 79(4): 512‑523.
• Food and Drug Administration (FDA). “Aquaculture Antibiotic Use Guidelines.” 2022.
• World Health Organization (WHO). “Guidelines for the Use of Antimicrobials in Aquaculture.” 2020.
• Cleveland Clinic. “Crustacean Health & Disease Overview.” 2023.
• NIH. “Oral Vaccine Development for Vibrio‑Associated Shell Disease.” 2023.
• Marine Biotechnology. “Probiotic and Immunostimulant Effects in Shrimp and Lobster.” 2020.

```